Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|DLYE5953A||RG 7841|RG-7841|RG7841||DLYE5953A is an antibody drug conjugate comprising of an anti-Ly6E monoclonal antibody linked to monomethyl auristatin E, with potential to inhibit tumor growth and proliferation (PMID: 32694157).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||DLYE5953A||Phase I||Actionable||In a Phase I trial, DLYE5953A treatment resulted in an overall objective response rate of 12% (8/68, all partial responses), and stable disease in 54% (37/68) of patients with advanced solid tumors, including a cohort of breast cancer patients with a partial response in 10% (3/29) and a cohort of non-small cell lung cancer patients with a partial response in 20% (5/25) (PMID: 32694157; NCT02092792).||32694157|
|Unknown unknown||lung non-small cell carcinoma||not applicable||DLYE5953A||Case Reports/Case Series||Actionable||In a Phase I trial, a patient with non-small cell lung carcinoma expressing Ly6e (IHC 3+) who initially responded to prior treatments including chemotherapy regimens and Opdivo (nivolumab), but then progressed, achieved a partial response with a 46% decrease in tumor size after 2 cycles of DLYE5953A treatment, but treatment was discontinued after cycle 6 due to disease progression (PMID: 32694157; NCT02092792).||32694157|
|Unknown unknown||triple-receptor negative breast cancer||not applicable||DLYE5953A||Case Reports/Case Series||Actionable||In a Phase I trial, a patient with triple-receptor negative breast cancer expressing Ly6e (IHC 3+), who progressed on prior treatments, achieved stable disease as best response with a 14% decrease of the primary tumor after 2 cycles of DLYE5953A treatment, but treatment was discontinued after cycle 5 due to disease progression (PMID: 32694157; NCT02092792).||32694157|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|